Furthermore, Chakrabarti et al. found that glutamate-oxaloacetate transaminase 1 (GOT1) and malic enzyme 1 (ME1) expression, both gene targets of NRF2, could be used as predictive markers in the treatment response to radiation therapy in NSCLC patients [145]. The gene discussed is ME1; the disease is non-small cell lung carcinoma.